These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 6155278)

  • 21. A prodrug of ADTN: selectivity of dopaminergic action and brain levels of ADTN.
    Horn AS; Kelly P; Westerink BH; Dijkstra D
    Eur J Pharmacol; 1979 Nov; 60(1):95-9. PubMed ID: 574829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic D-amphetamine and phencyclidine: effects on dopamine agonist and antagonist binding sites in the extrapyramidal and mesolimbic systems.
    Robertson HA
    Brain Res; 1983 May; 267(1):179-82. PubMed ID: 6860944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium ion modulates D2 receptor characteristics of dopamine agonist and antagonist binding sites in striatum and retina.
    Makman MH; Dvorkin B; Klein PN
    Proc Natl Acad Sci U S A; 1982 Jul; 79(13):4212-6. PubMed ID: 6213964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum.
    Seiler MP; Markstein R
    Mol Pharmacol; 1984 Nov; 26(3):452-7. PubMed ID: 6238231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uptake of (3H)-ADTN into dopaminergic neurons in the rabbit retina.
    Ehinger B
    Acta Physiol Scand; 1981 Apr; 111(4):511-2. PubMed ID: 7304214
    [No Abstract]   [Full Text] [Related]  

  • 26. Dopamine receptor binding in inbred mice: strain differences in mesolimbic and nigrostriatal dopamine binding sites.
    Boehme RE; Ciaranello RD
    Proc Natl Acad Sci U S A; 1981 May; 78(5):3255-9. PubMed ID: 6166945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Similar binding of 3H-ADTN and 3H-apomorphine to calf brain dopamine receptors.
    Seeman P; Woodruff GN; Poat JA
    Eur J Pharmacol; 1979 Apr; 55(2):137-42. PubMed ID: 456412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand.
    Damsma G; Bottema T; Westerink BH; Tepper PG; Dijkstra D; Pugsley TA; MacKenzie RG; Heffner TG; Wikström H
    Eur J Pharmacol; 1993 Nov; 249(3):R9-10. PubMed ID: 8287911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [3H]dihydroergocryptine binding to bovine striatal membranes defined by a low d-butaclamol concentration: antagonism by substituted benzamides.
    Lin CW; Maayani S; Wilk S
    Biochem Pharmacol; 1981 Jun; 30(11):1305-14. PubMed ID: 6168265
    [No Abstract]   [Full Text] [Related]  

  • 30. Binding of a conformationally restricted dopamine analogue, 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, to receptors on rat brain synaptic membranes.
    Roberts PJ; Woodruff GN; Poat JA
    Mol Pharmacol; 1977 May; 13(3):541-7. PubMed ID: 17829
    [No Abstract]   [Full Text] [Related]  

  • 31. The thermodynamics of agonist and antagonist binding to dopamine D-2 receptors.
    Kilpatrick GJ; el Tayar N; Van de Waterbeemd H; Jenner P; Testa B; Marsden CD
    Mol Pharmacol; 1986 Sep; 30(3):226-34. PubMed ID: 2943980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced dopaminergic binding during aging in the rodent striatum.
    Severson JA; Finch CE
    Brain Res; 1980 Jun; 192(1):147-62. PubMed ID: 6155174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of dopamine receptors by 3H-ADTN binding in calf adrenal zona glomerulosa.
    Bevilacqua M; Vago T; Scorza D; Norbiato G
    Biochem Biophys Res Commun; 1982 Oct; 108(4):1661-9. PubMed ID: 6295387
    [No Abstract]   [Full Text] [Related]  

  • 34. Kinetic and pharmacological profiles of the in vitro binding of the potent dopamine agonist [3H]N,N-dipropyl-5,6-dihydroxy-2-aminotetralin to rat striatal membranes.
    Mulder TB; Grol CJ; Dijkstra D; Horn AS
    Eur J Pharmacol; 1985 May; 112(1):73-9. PubMed ID: 4018139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the (+) and (-)-enantiomers of 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene on dopamine receptors and on dopamine uptake [proceedings].
    Andrews CD; Davis A; Freeman HS; McDermed JD; Poat JA; Woodruff GN
    Br J Pharmacol; 1978 Nov; 64(3):433P. PubMed ID: 719283
    [No Abstract]   [Full Text] [Related]  

  • 36. Simultaneous demonstration of the activation of presynaptic dopamine autoreceptors and postsynaptic dopamine receptors in vitro by N,N-dipropyl-5,6-ADTN.
    Stoof JC; Horn AS; Mulder AH
    Brain Res; 1980 Aug; 196(1):276-81. PubMed ID: 7397528
    [No Abstract]   [Full Text] [Related]  

  • 37. Involvement of both dopaminergic and alpha-adrenergic receptors in the hypomotility induced by dibenzoyl-6,7-ADTN.
    Sumners C; De Vries JB; Dijkstra D; Horn AS
    Eur J Pharmacol; 1981 Apr; 70(4):541-50. PubMed ID: 6113149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differentiation of solubilized dopamine receptors from spirodecanone binding sites in rat striatum.
    Gorissen H; Ilien B; Aerts G; Laduron P
    FEBS Lett; 1980 Nov; 121(1):133-8. PubMed ID: 6161839
    [No Abstract]   [Full Text] [Related]  

  • 39. The pKa of butaclamol and the mode of butaclamol binding to central dopamine receptors.
    Chrzanowski FA; McGrogan BA; Maryanoff BE
    J Med Chem; 1985 Mar; 28(3):399-400. PubMed ID: 2579238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Binding of [3H]SCH23390 to a non-dopaminergic site in bovine kidney.
    Hollis CM; Turner JD; Strange PG
    Biochem Pharmacol; 1992 May; 43(9):1947-55. PubMed ID: 1375829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.